A partial agonist for retinoid X receptor mitigates experimental colitis.

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, is a chronic gastrointestinal disorder.
• Dietary factors, like n-3 unsaturated fatty acids (e.g., docosahexaenoic acid), may offer protective effects against IBD.
• Docosahexaenoic acid's agonistic activity on retinoid X receptor (RXR) suggests RXR activation as a potential IBD therapeutic strategy.

Purpose of the Study:

• To evaluate the efficacy of a partial RXR agonist, CBt-PMN, in ameliorating dextran sodium sulfate-induced colitis.
• To investigate the molecular mechanisms underlying CBt-PMN's therapeutic effects in colitis models.

Main Methods:

• Dextran sodium sulfate (DSS)-induced colitis model in mice.
• Administration of the partial RXR agonist CBt-PMN.
• Analysis of pro-inflammatory cytokine levels (Tnf, Il6) in colon tissues and bone marrow-derived macrophages (BMDMs).
• Investigation of nuclear receptor involvement, including peroxisome proliferator-activated receptor δ (PPARδ) and nuclear hormone receptor 77 (Nur77).

Main Results:

• CBt-PMN administration significantly ameliorated colitis symptoms.
• CBt-PMN treatment led to down-regulation of pro-inflammatory cytokines Tnf and Il6 in colon-infiltrating monocytes and BMDMs.
• Activation of PPARδ/RXR and Nur77/RXR heterodimers by CBt-PMN was identified as a key mechanism suppressing inflammation.

Conclusions:

• Partial RXR agonist CBt-PMN demonstrates significant therapeutic potential for IBD.
• CBt-PMN mitigates gut inflammation by suppressing monocyte-mediated inflammatory responses via RXR activation.
• Targeting RXR, particularly through partial agonists like CBt-PMN, represents a viable therapeutic avenue for managing IBD.